Valencia, CA – August 28, 2017 – SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today that it has secured $30 million in Series D equity financing. The Series D financing will provide SetPoint with funding to further advance the clinical development of […]
Tag: Medtronic
Medtronic Receives CE Mark for Attain Stability(TM) Quad MRI SureScan(TM) Active-Fixation Heart Lead
DUBLIN – August 21, 2017 – Medtronic plc (NYSE: MDT) announced it has received CE (Conformité Européene) Mark for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead features novel, active-fixation technology that is designed […]
Minnesota Supreme Court allows shareholder suit over Medtronic-Covidien merger
Updated to clarify that MDT officers and directors were compensated for excise-tax based liabilities related to stock options, and not for capital gains. Medtronic (NYSE:MDT) shareholders seeking to sue the company claiming they were harmed by its $50 billion corporate inversion merger with Covidien will get their chance in court, the […]
Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology
DUBLIN- August 14, 2017 – Medtronic plc (NYSE: MDT) today announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) – the combination of aspirin and an anti-clotting medication – in patients implanted with the Resolute Onyx(TM) Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI). Designed to […]
Medtronic (MDT) Bags Approval for Avalus Valve in U.S. and Europe
DUBLIN – August 2, 2017 – Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic surgical valve for the treatment of aortic valve disease. The Avalus valve leverages proven surgical bioprosthetic valve concepts with added features designed to […]
Boca Raton Regional Hospital Using New Technology To Map Irregular Heart Rhythms Non-Invasively
NEWS PROVIDED BY Boca Raton Regional Hospital Aug 01, 2017, 12:24 ET BOCA RATON, Fla., Aug. 1, 2017 /PRNewswire-USNewswire/ — Boca Raton Regional Hospital is the first in Florida and one of only five centers nationally to non-invasively map irregular heartbeats in patients with chronic atrial fibrillation and other arrhythmias who have not responded adequately […]
Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing
DUBLIN – July 31, 2017 – Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery. Clinical data for the Evolut PRO valve […]
Cardinal Health Completes Acquisition of Medtronic’s Patient Recovery Business
DUBLIN, Ohio, July 30, 2017 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has completed the acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion. The acquisition was funded with a combination of $4.5 billion in new senior unsecured notes, existing cash and borrowings under our existing credit […]
Medtronic (MDT) First To Receive Health Canada Licence For MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
BRAMPTON, Ontario, July 26, 2017 (GLOBE NEWSWIRE) — Medtronic Canada, a subsidiary of Medtronic plc, today announced it has received a Health Canada licence and is launching its first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for heart failure. Heart failure causes or contributes to […]
SurModics (SRDX) Receives IDE Approval To Initiate Pivotal Trial Of The Surveil Drug-Coated Balloon
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial of the SurVeil™ drug-coated balloon (DCB). The randomized […]